Spots Global Cancer Trial Database for kras g12c
Every month we try and update this database with for kras g12c cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | NCT05375994 | Non Small Cell ... KRAS Activating... Advanced Cancer Metastatic Canc... Malignant Neopl... Malignant Neopl... | avutometinib (V... | 18 Years - | Verastem, Inc. | |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | NCT05853575 | Advanced Cancer Metastatic Canc... Malignant Neopl... | Adagrasib | 18 Years - | Mirati Therapeutics Inc. | |
| A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations | NCT05005234 | KRAS G12C | GFH925 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC | NCT06162221 | Non-Small Cell ... KRAS, NRAS, HRA... KRAS G12C-mutat... Lung Cancer Sta... | RMC-6291 RMC-6236 Pembrolizumab Cisplatin Carboplatin Pemetrexed | 18 Years - | Revolution Medicines, Inc. | |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | NCT05445843 | Locally Advance... | JDQ443 | 18 Years - | Novartis | |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | NCT04006301 | Neoplasms Advanced Solid ... Non-small Cell ... Colorectal Canc... | JNJ-74699157 | 18 Years - | Janssen Research & Development, LLC | |
| VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | NCT05374538 | Non-small Cell ... | VIC-1911 sotorasib | 18 Years - | Vitrac Therapeutics, LLC | |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | NCT06248606 | Non Small Cell ... NSCLC KRAS G12C | Adagrasib Stereotactic Ra... | 18 Years - | Hoosier Cancer Research Network | |
| VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | NCT05374538 | Non-small Cell ... | VIC-1911 sotorasib | 18 Years - | Vitrac Therapeutics, LLC | |
| AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC | NCT06068153 | Metastatic Non ... KRAS G12C | Sotorasib Lenvatinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC | NCT06162221 | Non-Small Cell ... KRAS, NRAS, HRA... KRAS G12C-mutat... Lung Cancer Sta... | RMC-6291 RMC-6236 Pembrolizumab Cisplatin Carboplatin Pemetrexed | 18 Years - | Revolution Medicines, Inc. | |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | NCT05315180 | Malignant Neopl... Metastatic Canc... | BPI-421286 | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | NCT05853575 | Advanced Cancer Metastatic Canc... Malignant Neopl... | Adagrasib | 18 Years - | Mirati Therapeutics Inc. | |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | NCT04613596 | Advanced Non-Sm... Metastatic Non-... | Adagrasib Adagrasib Adagrasib Adagrasib Pembrolizumab | 18 Years - | Mirati Therapeutics Inc. | |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | NCT04975256 | Advanced Cancer Metastatic Canc... Malignant Neopl... Malignant Neopl... Malignant Neopl... | MRTX849 BI 1701963 | 18 Years - | Mirati Therapeutics Inc. | |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | NCT04006301 | Neoplasms Advanced Solid ... Non-small Cell ... Colorectal Canc... | JNJ-74699157 | 18 Years - | Janssen Research & Development, LLC | |
| JDQ443 for KRAS G12C NSCLC Brain Metastases | NCT05999357 | Non Small Cell ... Brain Metastase... KRAS G12C | JDQ443 | 18 Years - | Maastricht University Medical Center | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | NCT04613596 | Advanced Non-Sm... Metastatic Non-... | Adagrasib Adagrasib Adagrasib Adagrasib Pembrolizumab | 18 Years - | Mirati Therapeutics Inc. | |
| Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer | NCT03647098 | KRAS G12C Non-small Cell ... KRAS G12D KRAS G12V KRAS G12R KRAS G12Y KRAS G13N | Chemotherapy. | 18 Years - | Hunan Province Tumor Hospital | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | NCT05074810 | Non Small Cell ... KRAS Activating... | avutometinib an... avutometinib an... | 18 Years - | Verastem, Inc. | |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | NCT03785249 | Advanced Cancer Metastatic Canc... Malignant Neopl... | MRTX849 Pembrolizumab Cetuximab Afatinib | 18 Years - | Mirati Therapeutics Inc. | |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | NCT05445843 | Locally Advance... | JDQ443 | 18 Years - | Novartis | |
| Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | NCT06343402 | Non-small Cell ... Metastatic Non-... NSCLC KRAS G12C Metastatic Lung... Advanced Lung C... | BBO-8520 Pembrolizumab | 18 Years - | TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics | |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | NCT05315180 | Malignant Neopl... Metastatic Canc... | BPI-421286 | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | NCT06248606 | Non Small Cell ... NSCLC KRAS G12C | Adagrasib Stereotactic Ra... | 18 Years - | Hoosier Cancer Research Network | |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | NCT06244771 | Advanced Solid ... Solid Tumor, Ad... Unresectable So... Metastatic Soli... Non Small Cell ... Colorectal Canc... KRAS G12C Pancreatic Canc... | FMC-376 | 18 Years - | Frontier Medicines Corporation | |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | NCT06244771 | Advanced Solid ... Solid Tumor, Ad... Unresectable So... Metastatic Soli... Non Small Cell ... Colorectal Canc... KRAS G12C Pancreatic Canc... | FMC-376 | 18 Years - | Frontier Medicines Corporation | |
| Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities | NCT05311709 | Lung Cancer NSCLC, Stage II... NSCLC Stage IV Lung Cancer Sta... Mutation Cancer Cancer, Lung | sotorasib | 18 Years - | Vestre Viken Hospital Trust | |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | NCT04006301 | Neoplasms Advanced Solid ... Non-small Cell ... Colorectal Canc... | JNJ-74699157 | 18 Years - | Janssen Research & Development, LLC | |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT04699188 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Colo... Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | JDQ443 TNO155 tislelizumab | 18 Years - | Novartis | |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | NCT05485974 | Lung Cancer Non Small Cell ... Colorectal Canc... Cancer of Pancr... Colon Cancer Solid Tumor Cancer | HBI-2438 | 18 Years - | HUYABIO International, LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
